Business Context and Reporting Period
Veracyte, Inc. filed a Form 8-K on December 3, 2019, reporting the entry into a Material Definitive Agreement and the completion of an asset acquisition. The Company entered into a License and Asset Purchase Agreement (LAPA) with NanoString, Inc. to acquire the nCounter FLEX Analysis System license and specific diagnostic assets.
Key Financial Metrics and Transaction Terms
This filing details a strategic acquisition rather than periodic financial performance. The transaction consideration includes:
- Cash Payment: $40,000,000 paid to NanoString.
- Equity Consideration: 376,732 shares of Veracyte common stock, valued at approximately $10,000,000 based on the average closing price for the ten trading days prior to the closing date.
- Contingent Milestone Payments: Up to $10,000,000 in aggregate, payable upon the commercial launch of three new diagnostic tests on the FLEX System (excluding Prosigna and LymphMark). Payments are structured as $3,500,000, $3,500,000, and $3,000,000.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the Company.
Material Changes and Acquired Assets
Veracyte acquired exclusive worldwide licensing rights to the nCounter FLEX Analysis System for in vitro diagnostic use. Additionally, the Company acquired assets related to:
- Prosigna Breast Cancer Prognostic Gene Signature Assay.
- LymphMark Lymphoma Subtyping Test.
- Associated assay software modules.
Veracyte assumed certain liabilities, including ongoing third-party royalty obligations related to Prosigna and LymphMark. The Company also entered into service and supply agreements for the manufacture of these tests and the FLEX System.
Outlook, Risks, and Contingencies
Equity Restrictions: NanoString is restricted from selling the Equity Consideration for 90 days post-closing. Thereafter, sales are limited to 10% of the average daily trading volume over the preceding 30 days. Veracyte must register these shares for resale within 90 days.
Financial Reporting Waiver: The Company obtained an SEC waiver from providing full pro forma financial information. Instead, it will provide an audited statement of assets acquired and liabilities assumed (Abbreviated Financial Statements) within 71 days of the filing deadline or in its 2019 Form 10-K.
Risks: The filing notes that representations and warranties in the LAPA are for contractual risk allocation and should not be relied upon as factual statements by stockholders. Certain portions of the agreement were omitted to prevent competitive harm.
Investor Verification Checklist
- Verify the impact of the $40 million cash outflow on Veracyte's current liquidity position.
- Confirm the dilution effect of issuing 376,732 shares of common stock.
- Review the specific commercialization milestones required to trigger the $10 million in contingent payments.
- Monitor the upcoming filing of the Abbreviated Financial Statements for the final allocation of the purchase price.
- Assess the magnitude of the assumed third-party royalty obligations for Prosigna and LymphMark.